search
Back to results

Comparison of a Drug and Placebo in the Prevention of Migraine Headaches

Primary Purpose

Headache, Migraine

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
ethosuximide
placebo comparator
Sponsored by
US Department of Veterans Affairs
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Headache, Migraine focused on measuring headache, migraine, depression, disability evaluation, weight gain

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Must be a veteran.
  • The number of migraine days per 4-week period is to be 4-14 for a period of 3 months prior to screening for entry into the trial.
  • Migraine must have been occurring for 6 months preceding entry into the trial and age of onset should be before age 60 years.
  • Migraine must be at least moderate severity and interrupt daily activities in some respect at least 3 times per month.
  • As long as the veteran can easily distinguish nonmigraine headaches from migraine, there is no limit on the number of non migraine headache days allowed. "Transformed migraine" headaches due to medication over usage will be excluded according to exclusion criteria #4.
  • Migraine diagnosis:

Veterans with headache must have migraine categorized using the International Headache Society (I.H.S.) criteria as illustrated below for the two main types with and without aura.

Criteria for migraine without aura (I.H.S. 1.1)

  • > 5 attacks
  • headache lasting 4-72 hours when untreated or not successfully treated.
  • headache with two of the following characteristics

    • unilateral,
    • pulsating,
    • moderate to severe intensity,
    • aggravation by exertion.
  • one of the following occurs with headache

    • nausea and/or vomiting
    • photophobia and phonophobia

Criteria for migraine with aura (I.H.S. 1.2)

  • at least 2 attacks
  • at least three of the following characteristics:

    • One or more fully reversible aura symptoms indicating focal cerebral cortical - and/or brain stem dysfunction.

One or more aura symptoms of the following types:

  • Homonymous visual disturbance
  • Unilateral parenthesis and/or numbness
  • Unilateral weakness
  • Aphasia or unclassifiable speech difficulty

    • At least one aura symptom develops gradually over more than 4 minutes or, 2 or more symptoms occur in succession.
    • No aura symptom lasts more than 60 minutes. If more than one aura symptom is present, accepted duration is proportionally increased.
    • Headache follows aura with a free interval of less than 60 minutes. (It may also begin before or simultaneously with the aura). Headache, nausea and/or photophobia usually follow neurological aura symptoms directly or after a free interval of less than an hour. The headache usually lasts 4-72 hours, but may be completely absent (1.2.5, acephalgic migraine).

Exclusion Criteria:

  • Veterans with migraine plus other systemic disorder will be excluded if migraine onset was temporally related to onset of the systemic disorder.
  • Blood pressure elevations (must be < borderline values 135/85 for 4 weeks before enrollment into the study). Current treatment for hypertension with beta-blockers, calcium channel blockers, or ace inhibitors not allowed.
  • Use of other prophylactic migraine drugs (requires a washout phase) and cannot have failed more than two other prophylactic drugs for migraine.
  • Excessive use of acute pain medicines, including narcotics (>10 days month). Those using non-narcotics could be tapered off over 4-8 weeks.
  • Receiving disability or seeking disability for headache or chronic pain.
  • Significant neck pain or cervicogenic contributors to chronic headache.
  • Significant depression, anxiety, post-traumatic stress disorder, or other disabling psychiatric condition.
  • Known allergies or serious side effects with ESX or succinimides in the past.
  • Known liver or significant renal disease.
  • Women veterans of child-bearing age who do not have adequate birth control.
  • Chronic bone marrow suppression.
  • Using psychogenic or other sedating maintenance drugs.
  • History of porphyria.
  • History of cluster headache. 15.History of other CNS disease.
  • Age younger than 18 years and greater than 65.
  • Women veterans who are breastfeeding.
  • Veterans with familial hemiplegic migraine (FHM).

Ongoing exclusions during the study:

  • The addition of other migraine prophylactic headache medicines is not allowed. 2. New drugs cannot be added that aggravate headache (nitrates, dipyridamole, niacin).

Sites / Locations

  • VA Pittsburgh Health Care System

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Arm 1-ethosuximide

Arm 2-placebo comparator

Arm Description

ethosuximide blinded capsules of 250mg ESX; titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed "30mg"/kg/d) vs maximum tolerability

placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed "30mg"/kg/d) vs maximum tolerability

Outcomes

Primary Outcome Measures

Migraine Headache Days Per 4 Week Period Comparing the Last 4 Weeks of Treatment to a 4 Week Pre-treatment Baseline.
Compare number of migraine headache days pre and post treatment between the ESX and placebo group. Study terminated early-no outcome data available. The single subject assigned to study drug did not actually take it according to subsequent review of ESX drug levels.

Secondary Outcome Measures

Full Information

First Posted
May 10, 2010
Last Updated
August 11, 2015
Sponsor
US Department of Veterans Affairs
Collaborators
Thomas Jefferson University, University of Pittsburgh
search

1. Study Identification

Unique Protocol Identification Number
NCT01122381
Brief Title
Comparison of a Drug and Placebo in the Prevention of Migraine Headaches
Official Title
Pharmacologic and Genetic Evaluation of a C. Elegans Model for Migraine
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Terminated
Why Stopped
poor recruitment
Study Start Date
December 2011 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
April 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
US Department of Veterans Affairs
Collaborators
Thomas Jefferson University, University of Pittsburgh

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine whether ethosuximide works better than placebo in the prevention of episodic migraine among veterans.
Detailed Description
Chronic and episodic headaches in veteran populations include migraine, transformed migraine, and post-traumatic headache with migrainous features. More and better prophylactic drugs with fewer side effects (such as weight gain) are needed to treat these disabling, refractory conditions which generally have less than a 50% response rate to preventative treatments. Rare forms of severe familial hemiplegic migraine (FHM) are considered channelopathies and can be caused by mutations in a calcium channel gene. Serotonin is also known to be a critical neurotransmitter in migraine based on the pharmacology of acute and preventative treatments. We previously identified a "migraine" signaling pathway in an invertebrate C. elegans "hemiplegic migraine" model of a mutant calcium channel upstream from transforming growth factor-beta (TGF-beta) and showed that low serotonin levels can be rescued by treatment with the childhood antiepileptic drug ethosuximide (ESX). Objective: We propose to test our findings from this invertebrate migraine model to determine its relevance to humans in the prevention of episodic migraine. Primary Aim: Determine whether ethosuximide (ESX) will be significantly more effective than placebo in reducing migraine headache days. We propose a 3 year, double blind, phase 1/2 randomized, 2:1 ESX:placebo controlled parallel trial in episodic migraineurs comparing migraine headache days during the last 4 weeks of treatment to a pre-treatment 4 week baseline.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Headache, Migraine
Keywords
headache, migraine, depression, disability evaluation, weight gain

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm 1-ethosuximide
Arm Type
Experimental
Arm Description
ethosuximide blinded capsules of 250mg ESX; titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed "30mg"/kg/d) vs maximum tolerability
Arm Title
Arm 2-placebo comparator
Arm Type
Placebo Comparator
Arm Description
placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed "30mg"/kg/d) vs maximum tolerability
Intervention Type
Drug
Intervention Name(s)
ethosuximide
Other Intervention Name(s)
zarontin
Intervention Description
ethosuximide (ESX)
Intervention Type
Other
Intervention Name(s)
placebo comparator
Intervention Description
placebo
Primary Outcome Measure Information:
Title
Migraine Headache Days Per 4 Week Period Comparing the Last 4 Weeks of Treatment to a 4 Week Pre-treatment Baseline.
Description
Compare number of migraine headache days pre and post treatment between the ESX and placebo group. Study terminated early-no outcome data available. The single subject assigned to study drug did not actually take it according to subsequent review of ESX drug levels.
Time Frame
4 weeks, end of treatment and pre-treatment baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Must be a veteran. The number of migraine days per 4-week period is to be 4-14 for a period of 3 months prior to screening for entry into the trial. Migraine must have been occurring for 6 months preceding entry into the trial and age of onset should be before age 60 years. Migraine must be at least moderate severity and interrupt daily activities in some respect at least 3 times per month. As long as the veteran can easily distinguish nonmigraine headaches from migraine, there is no limit on the number of non migraine headache days allowed. "Transformed migraine" headaches due to medication over usage will be excluded according to exclusion criteria #4. Migraine diagnosis: Veterans with headache must have migraine categorized using the International Headache Society (I.H.S.) criteria as illustrated below for the two main types with and without aura. Criteria for migraine without aura (I.H.S. 1.1) > 5 attacks headache lasting 4-72 hours when untreated or not successfully treated. headache with two of the following characteristics unilateral, pulsating, moderate to severe intensity, aggravation by exertion. one of the following occurs with headache nausea and/or vomiting photophobia and phonophobia Criteria for migraine with aura (I.H.S. 1.2) at least 2 attacks at least three of the following characteristics: One or more fully reversible aura symptoms indicating focal cerebral cortical - and/or brain stem dysfunction. One or more aura symptoms of the following types: Homonymous visual disturbance Unilateral parenthesis and/or numbness Unilateral weakness Aphasia or unclassifiable speech difficulty At least one aura symptom develops gradually over more than 4 minutes or, 2 or more symptoms occur in succession. No aura symptom lasts more than 60 minutes. If more than one aura symptom is present, accepted duration is proportionally increased. Headache follows aura with a free interval of less than 60 minutes. (It may also begin before or simultaneously with the aura). Headache, nausea and/or photophobia usually follow neurological aura symptoms directly or after a free interval of less than an hour. The headache usually lasts 4-72 hours, but may be completely absent (1.2.5, acephalgic migraine). Exclusion Criteria: Veterans with migraine plus other systemic disorder will be excluded if migraine onset was temporally related to onset of the systemic disorder. Blood pressure elevations (must be < borderline values 135/85 for 4 weeks before enrollment into the study). Current treatment for hypertension with beta-blockers, calcium channel blockers, or ace inhibitors not allowed. Use of other prophylactic migraine drugs (requires a washout phase) and cannot have failed more than two other prophylactic drugs for migraine. Excessive use of acute pain medicines, including narcotics (>10 days month). Those using non-narcotics could be tapered off over 4-8 weeks. Receiving disability or seeking disability for headache or chronic pain. Significant neck pain or cervicogenic contributors to chronic headache. Significant depression, anxiety, post-traumatic stress disorder, or other disabling psychiatric condition. Known allergies or serious side effects with ESX or succinimides in the past. Known liver or significant renal disease. Women veterans of child-bearing age who do not have adequate birth control. Chronic bone marrow suppression. Using psychogenic or other sedating maintenance drugs. History of porphyria. History of cluster headache. 15.History of other CNS disease. Age younger than 18 years and greater than 65. Women veterans who are breastfeeding. Veterans with familial hemiplegic migraine (FHM). Ongoing exclusions during the study: The addition of other migraine prophylactic headache medicines is not allowed. 2. New drugs cannot be added that aggravate headache (nitrates, dipyridamole, niacin).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kathy L Gardner, MD
Organizational Affiliation
VA Pittsburgh Health Care System
Official's Role
Principal Investigator
Facility Information:
Facility Name
VA Pittsburgh Health Care System
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15240
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Comparison of a Drug and Placebo in the Prevention of Migraine Headaches

We'll reach out to this number within 24 hrs